Produced in partnership with IBTV, our Roving Reporter series captures real-time perspectives from across the life sciences industry. Filmed on the show floor at ASGCT 2026 in Boston, this episode brings together leading voices from across cell and gene therapy to ask how the sector should rethink value, access, and affordability as more advanced therapies move from clinical trials into routine care.
Although cell and gene therapies have demonstrated the potential to transform – and sometimes fundamentally alter – the course of serious diseases, high manufacturing costs, complex delivery pathways, and uncertain reimbursement models continue to restrict patient access. Industry leaders argue that progress will depend on reducing production costs, treating patients earlier, expanding delivery beyond specialist centers, and assessing value over the long term rather than focusing solely on the upfront price of a therapy.
Featuring insights from Emmanuelle Cameau of Cytiva, David Radspinner of VintaBio, Heather Purvis of Title21 Health Solutions, Andrew Scheffler of ScaleReady, Francesca Vidali of ReiThera, John Tomtishen of Catalent, Jimmy Vanhove of Viralgen, Natalia Elizalde of VIVEbiotech, Bryan Deuber of Andelyn, Andrew Lewin of Lentitek, and Nick Randall of Repligen, the discussion explores how manufacturers, regulators, healthcare systems, payers, and patient advocates can work together to make these potentially transformative treatments more accessible and sustainable.
Watch the video below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
